Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 139
- Registration Number
- NCT05645380
- Locations
- 🇺🇸
The University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States
🇺🇸The University of Kansas Cancer Center - Main Hospital, Kansas City, Kansas, United States
🇺🇸The University of Kansas Cancer Center - Westwood, Kansas City, Kansas, United States
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 236
- Registration Number
- NCT05638594
- Locations
- 🇨🇳
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Akeso
- Target Recruit Count
- 114
- Registration Number
- NCT05636267
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, China
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 400
- Registration Number
- NCT05635708
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇦🇺Chris Obrien Lifehouse, Camperdown, New South Wales, Australia
🇰🇷Seoul National University Bundang Hospital, Seongnamsi, Gyeonggi-do, Korea, Republic of
Study of Novel Treatment Combinations in Patients With Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-01
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 593
- Registration Number
- NCT05633667
- Locations
- 🇧🇷
Hospital Mae de Deus, Porto Alegre, Brazil
🇧🇷Hospital Sao Lucas da PUC Rio Grande do Sul,Substudy-03, Porto Alegre, Brazil
🇬🇧Birmingham Heartlands Hospital,Substudy-03, Birmingham, United Kingdom
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer
- Conditions
- Interventions
- Drug: CarboplatinDrug: CisplatinProcedure: Computed TomographyBiological: DurvalumabDrug: EtoposideRadiation: Image Guided Radiation TherapyDrug: PaclitaxelDrug: PemetrexedProcedure: Positron Emission TomographyOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 474
- Registration Number
- NCT05624996
- Locations
- 🇺🇸
UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
🇺🇸Ascension Borgess Hospital, Kalamazoo, Michigan, United States
🇺🇸Benefis Sletten Cancer Institute, Great Falls, Montana, United States
Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05611879
- Locations
- 🇨🇳
Beijing Tsinghua Chang Gung Hospital, Beijing, Beijing, China
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT05605535
- Locations
- 🇮🇳
King George Hospital, Visakhapatnam, Andhra Pradesh, India
🇮🇳Omega Hospitals, Visakhapatnam, Andhra Pradesh, India
🇮🇳Kailash Cancer Hospital and Research Centre, Vadodara, Gujarat, India
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 350
- Registration Number
- NCT05599984
- Locations
- 🇩🇪
Klinikum der Universität München - Campus Innenstadt /ID# 259412, Munich, Bayern, Germany
🇺🇸Banner MD Anderson Cancer Ctr /ID# 260129, Gilbert, Arizona, United States
🇺🇸City Of Hope Comprehensive Cancer Center /ID# 271295, Duarte, California, United States
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- RayzeBio, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT05595460
- Locations
- 🇵🇷
Research Facility, San Juan, Puerto Rico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.